INHX misses primary endpoint... If you buy $heff's scam biotech picks you'll end up holding the bag. Everyone claims he's sooo smart, he does all this great DD... All he does is buy low float companies that have some binary event and has his followers drive up the stock as he sells it. Its classic pump and dump. Good Luck everyone that follows him... His success has been based on you and now you're holding the bag.
I can't blame the guy, he's made some good picks and now he's got a ton of followers who make the price go up for him. He could pretty much put couple hundred g's on each trade and scalp for 10% every time. Pump and dump but a smart guy.
BIO: I don't know or even care who Sheff is, but the INHX study was a multiple dose PII study intended to determine the efficacious doses to use in pivotal PIII, whereas the CYTK study was a SINGLE DOSE EoE study. CYTK's compound may or may not eventually fail, but this study was not intended to demonstrate that...just to provide a hint as to whether it would be worthwhile to go into the more expensive multiple dose studies, and in that regard, it was successful.
I started trading a long time ago as a 17 y.o. I recommend quietly listening and learning how to conduct proper due diligence, and especially learning to separate the good info from the bs.